# A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Study · id `cardio:ct-nct04349072` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04349072](<https://clinicaltrials.gov/study/NCT04349072>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04349072

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

## Technical summary

Registry record NCT04349072. Randomized; quadruple masking; primary purpose treatment. Start 2020-07-06 (actual); primary completion 2022-02-07 (actual). Results posted on 2023-03-07.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT04349072, source copy `cardio:ctgov-nct04349072-2025-05-23`, retrieved 2026-10-31)
- Started: 2020-07-06 (actual) (ClinicalTrials.gov record NCT04349072, source copy `cardio:ctgov-nct04349072-2025-05-23`, retrieved 2026-10-31)
- Primary completion: 2022-02-07 (actual) (ClinicalTrials.gov record NCT04349072, source copy `cardio:ctgov-nct04349072-2025-05-23`, retrieved 2026-10-31)
- Completion: 2024-05-20 (actual) (ClinicalTrials.gov record NCT04349072, source copy `cardio:ctgov-nct04349072-2025-05-23`, retrieved 2026-10-31)
- Results first posted: 2023-03-07 (ClinicalTrials.gov record NCT04349072, source copy `cardio:ctgov-nct04349072-2025-05-23`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04349072, source copy `cardio:ctgov-nct04349072-2025-05-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04349072-2025-05-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
- Acronym: VALOR-HCM
- Condition: HOCM, Hypertrophic Obstructive Cardiomyopathy
- Intervention (Drug): Mavacamten
- Intervention (Drug): Placebo
- Lead sponsor: Bristol-Myers Squibb
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record: Mavacamten (`cardio:mavacamten`)
- Registry lists this organization as the lead sponsor: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy (`cardio:pubmed-35798455`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study (`cardio:pubmed-36335645`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks (`cardio:pubmed-36335531`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial (`cardio:pubmed-37639243`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial (`cardio:pubmed-39221824`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial (`cardio:pubmed-39254622`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM (`cardio:pubmed-39556124`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ec5c1671c0410cf458845ead46d3ba389406a73ca61eba1612004d31a6d2e318
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
